EU Health Innovation
26 elements
Invalid Date
EMA Backs First Combined COVID-19 and Flu Vaccine
Citizens over 50 may soon receive protection against both flu and COVID-19 with just one shot.
Invalid Date
EMA Recommends 12 New Medicines for EU Approval
EMA recommends 12 new treatments, including options for rare and paediatric diseases.
Invalid Date
New EU Guidance for Clinical Trials During Emergencies
New EU rules to ensure quicker, safer clinical trials during health crises.
Invalid Date
EMA Issues Guidance on Clinical Trials
New EU guidance aims to improve clinical trial conduct during health crises.
Invalid Date
New EU Reference Labs for Public Health Announced
EU bolstering public health infrastructure by designating specialized reference labs.
Invalid Date
EDPB & EDPS on harmonising clinical trials
Data protection watchdogs call for safeguards in harmonizing clinical trials.
Invalid Date
EDPB Supports Biotech Act, Seeks Health Data Safeguards
EU data watchdogs push for strong data protection in biotech research.
Invalid Date
EU Reference Labs for Public Health - Open Calls
New EU Reference Labs will improve public health and diagnostic testing standards across the EU.
Invalid Date
EMA Highlights from March PRAC Meeting
Safety update on chikungunya vaccine: risk of aseptic meningitis.
Invalid Date
Joint Opinion on European Biotech Act Proposal
EU data protection watchdogs want safeguards for health data in Biotech Act.
Invalid Date
EDPB Supports Biotech Act with Data Safeguards
Stronger data protection requested for health data in EU Biotech Act.
Invalid Date
ECDC & Africa CDC Strengthen Health Security Ties
ECDC and Africa CDC join forces to tackle infectious diseases.
Invalid Date
EMA Introduces New PRIME Tools for Medicines
EMA enhances PRIME scheme to speed up development of medicines for unmet needs
Invalid Date
EMA: New Medicines Development Tools
Faster development of innovative EU medicines
Invalid Date
New PRIME Tools to Accelerate Development of Medicines in the EU
Invalid Date
EMA: New Tools to Speed Medicine Development
EMA boosts medicine development for unmet needs with new PRIME tools.
Invalid Date
EMA Restricts Use of Tecovirimat SIGA
Mpox treatment faces restriction due to updated clinical data.
Invalid Date
EMA Recommends New Lung Cancer Treatment
New lung cancer treatment gets EMA nod, expanding therapy options.
Invalid Date
EMA Restricts Use of Tecovirimat SIGA
EMA advises against using Tecovirimat SIGA for mpox treatment.
Invalid Date
EMA: New treatment for relapsed lung cancer approved
New treatment option becomes available for relapsed small cell lung cancer patients.
Invalid Date
EMA Consults on Reducing Animal Use in Drug Development
New EMA consultation seeks to reduce animal use in preclinical drug research.
Invalid Date
EMA consults on reducing animal use
EMA consults on methodology to reduce animal testing for new medicines.
Invalid Date
ECDC supports Latvia leptospirosis outbreak review
Improving EU preparedness for leptospirosis and other outbreaks through lessons learned.
Invalid Date
ECDC Reviews Latvia's Leptospirosis Response
Improving EU preparedness for waterborne disease outbreaks, future responses will be faster.
Invalid Date
New Lung Cancer Treatment Recommended by EMA
EMA recommends new lung cancer treatment, offering hope for patients in the EU.
Invalid Date
Lung Cancer: New Treatment Approved in the EU
New treatment offers hope for relapsed lung cancer patients in EU.
The European Union is actively fostering health innovation through several key initiatives. The European Medicines Agency (EMA) is enhancing its PRIME scheme with new tools designed to accelerate the assessment and approval process for medicines addressing unmet medical needs, streamlining communication and reducing development bottlenecks. In parallel, the European Commission is establishing new EU Reference Laboratories (EURLs) for public health to standardize diagnostic testing and provide scientific expertise, strengthening disease surveillance and preparedness for cross-border health threats. The European Centre for Disease Prevention and Control (ECDC) is also collaborating with the Africa CDC to improve global health security through enhanced surveillance, data sharing, and joint research.
These activities matter significantly for both citizens and businesses. For citizens, the faster development and approval of innovative therapies, facilitated by the enhanced PRIME scheme, means quicker access to potentially life-saving treatments. The strengthening of public health infrastructure, supported by the EURLs and international collaborations, contributes to better preparedness and response to infectious disease outbreaks. For businesses, the streamlined assessment processes and harmonized standards create a more predictable and efficient regulatory environment, fostering innovation and investment in the health sector. However, the European Data Protection Board (EDPB) and the European Data Protection Supervisor (EDPS) are working to safeguard the data protection of EU citizens.
Looking ahead, the EU's focus on health innovation appears to be heading towards a more integrated and data-driven approach. As demonstrated by the EDPB and EDPS's recent joint opinion on the European Biotech Act, data governance will play a pivotal role. Harmonization of clinical trials requires specific safeguards for sensitive health data, emphasizing transparency, consent, and purpose limitation. These measures suggest a future where innovation and ethical considerations are carefully balanced, ensuring that advancements in health technology are accompanied by robust protections for individual rights and data privacy.